VIENNA, March 31 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it will host a conference call today to discuss the U.S. Food and Drug Administration's (FDA) approval of IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE). The initial target for use of Intercell's vaccine - the only such product currently manufactured for the U.S. market - will be adult travelers and military personnel who visit or are deployed to affected countries, including India, China, and other parts of Asia.
Conference Call Details Time: 3 p.m. CET, 2 p.m. GMT and 9 a.m. EDT. Chairpersons: Gerd Zettlmeissl (CEO) and Thomas Lingelbach (COO and Managing Director Intercell Biomedical Ltd., Scotland) Dial-In: Austria: +43 (0)2682 205 62 92 Germany: +49 (0)69 589 990 507 Switzerland: +41 (0)434 56 92 61 US: +1 334 323 62 01 UK: +44 (0)20 7131 2799
Please quote "Intercell Call" and an operator will then put you through to the Intercell conference call.
The presentation will be made available on the Intercell website prior to the conference call.
About Japanese Encephalitis
Japanese Encephalitis is a mosquito-borne infection that strikes 30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths (both probably an underestimate due to underreporting and other factors). Up to 50 percent of survivors have persistent neurological sequelae. Japanese Encephalitis is the leading cause of viral neurological disease and disability in Asia and the most important viral encephalitis in Asia. The disease is most common in several developing countries in Asia, including India and China. As there is no specific treatment for JE, health care experts recommend vaccination as the only highly effective protection for the millions of travelers and military personnel who live in or trav
|SOURCE Intercell AG|
Copyright©2009 PR Newswire.
All rights reserved